Sign up for our daily briefing

Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on the day's biggest business stories

Subscribe to Axios Closer for insights into the day’s business news and trends and why they matter

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Stay on top of the latest market trends

Subscribe to Axios Markets for the latest market trends and economic insights. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sports news worthy of your time

Binge on the stats and stories that drive the sports world with Axios Sports. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Tech news worthy of your time

Get our smart take on technology from the Valley and D.C. with Axios Login. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Get the inside stories

Get an insider's guide to the new White House with Axios Sneak Peek. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Denver news?

Get a daily digest of the most important stories affecting your hometown with Axios Denver

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Des Moines news?

Get a daily digest of the most important stories affecting your hometown with Axios Des Moines

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Twin Cities news?

Get a daily digest of the most important stories affecting your hometown with Axios Twin Cities

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Tampa Bay news?

Get a daily digest of the most important stories affecting your hometown with Axios Tampa Bay

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Charlotte news?

Get a daily digest of the most important stories affecting your hometown with Axios Charlotte

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Photo: Allen J. Schaben / Los Angeles Times via Getty Images

The European Medicines Agency (EMA) said Tuesday that unusual blood clots should be listed as a "very rare" side effect of Johnson & Johnson's coronavirus vaccine, but that the benefits of the shot still outweigh the risks.

Why it matters: The agency's determination of a "possible link" to a rare kind of blood clot comes ahead of an expected ruling by the U.S. FDA this week on whether to lift its pause on the J&J vaccine rollout.

Details: Since the J&J vaccine has not yet been distributed in Europe outside of clinical trials, the data that the EMA reviewed came from the eight reports of rare blood clots reported in the U.S. out of 7 million total doses administered.

  • "COVID-19 is associated with a risk of hospitalisation and death. The reported combination of blood clots and low blood platelets is very rare, and the overall benefits of COVID-19 Vaccine Janssen in preventing COVID-19 outweigh the risks of side effects," the EMA said in a statement.
  • The agency recently made a similar recommendation about the AstraZeneca vaccine, determining that the benefits of its protection against COVID-19 outweigh the risks of rare blood clots.

Between the lines: Most Americans support the pause in distribution of the Johnson & Johnson COVID-19 vaccine, and so far there's no evidence that it's leading to broader vaccine hesitancy, according to the latest installment of the Axios/Ipsos Coronavirus Index.

Go deeper

Axios-Ipsos poll: Americans say J&J pause was the right call

Data: Axios/Ipsos Poll; Note: 3.3% margin of error; Chart: Andrew Witherspoon/Axios

Most Americans support the pause in distribution of the Johnson & Johnson COVID-19 vaccine, and so far there's no evidence that it's leading to broader vaccine hesitancy, according to the latest installment of the Axios/Ipsos Coronavirus Index.

Driving the news: In our weekly national survey, 91% of respondents were aware of the temporary pause recommended by the Food and Drug Administration and the Centers for Disease for Control and Prevention. Of those, 88% said the pause was a responsible decision.

State Department to issue travel advisories for 80% of the world

Photo: Ying Tang/NurPhoto via Getty Images

The State Department announced Monday that it will be issuing "do not travel" guidelines for roughly 80% of countries worldwide and urged Americans to "reconsider all travel abroad."

Why it matters: The announcement emphasizes the ongoing severity of the COVID-19 pandemic, despite a ramped up domestic vaccination campaign and many states moving to reopen. Globally, cases continue to surge.

Caitlin Owens, author of Vitals
Apr 20, 2021 - Health

Where seniors remain vulnerable to the coronavirus

Expand chart
Data: CDC and Simon Willison; Note: The last reliable figure reported for New Hampshire was 83.9% on April 6, 2021; Chart: Danielle Alberti/Axios

More than 80% of Americans 65 and older have received at least one dose of a coronavirus vaccine, per the CDC, but millions across the country remain unvaccinated — particularly in the South.

Why it matters: Seniors who have yet to receive their shot remain highly vulnerable to the virus even as the country overall becomes safer.